CRISPR-based genome engineering Vs Covid19

09 Dec 2020

The gene-targeting and gene-editing technology is proving useful in the fight against Covid19. The need for these transformative tools, technologies and approaches to life science research and development is now greater than ever. In the next decade, we will see clinical trials emerge that apply gene editing to the treatment of more common diseases, like heart disease and diabetes. This session helps us understand; what they can and cannot do, and what they cost? What are the policies to guide how life sciences research in the age of genomics and machine learning?

Trevor Martin, Co-founder & CEO - Mammoth Biosciences
Shamim Nabuuma Kaliisa, Founder and Executive Director - Chil (Community Healthcare Innovation) AI Lab

Innovation Partner

GFS 2020


Register now to be the first to hear about our special offers, exhibitor and speaker announcement, news about our features and so much more.

Follow us